Best Practices for Implementing AI in Aggregate Reporting for Pharma

The pharmaceutical industry is increasingly leveraging artificial intelligence (AI) to streamline critical functions. One of the key areas where AI is demonstrating transformative potential is aggregate reporting—the process of compiling safety data for regulatory submissions, risk assessments, and benefit-risk evaluations. Aggregate reports such as Periodic Safety Update Reports (PSURs), Periodic Benefit-Risk Evaluation Reports (PBRERs), and Development Safety Update Reports (DSURs) are complex, data-intensive, and subject to strict timelines and regulatory scrutiny.

AI can dramatically reduce the burden of manual data handling, improve accuracy, and accelerate reporting cycles. However, successful implementation of AI in aggregate reporting requires a strategic approach. In this blog, we’ll explore best practices for effectively integrating AI into aggregate reporting processes in the pharmaceutical industry.

1. Understand the Regulatory Landscape

Before implementing AI, it's crucial to understand the regulatory expectations surrounding aggregate reports. Regulatory bodies like the EMA, FDA, and MHRA expect comprehensive, high-quality safety data, with clear documentation of methodologies and transparent decision-making.

Best Practices:

• Stay updated with guidelines such as ICH E2C(R2), E2F, and GVP Module VII.

• Ensure AI tools are validated and comply with GxP and 21 CFR Part 11 standards.

• Involve regulatory affairs teams early to interpret how AI implementation might impact submission quality or inspection readiness.

2. Define Clear Objectives and Use Cases

Successful AI adoption starts with clearly defining what you aim to achieve. Are you aiming to reduce the time spent on data extraction? Improve signal detection accuracy? Or enhance narrative generation?

Best Practices:

• Conduct a gap analysis to identify inefficiencies in current reporting workflows.

• Prioritize use cases based on impact, feasibility, and regulatory risk.

• Develop a roadmap aligning AI implementation with strategic business goals and compliance requirements.

3. Choose the Right AI Technologies

AI is an umbrella term that encompasses machine learning (ML), natural language processing (NLP), robotic process automation (RPA), and more. Each technology serves different functions in aggregate reporting.

Best Practices:

• Use NLP for extracting insights from unstructured data like literature and case narratives.

• Leverage ML algorithms for pattern recognition in safety trends.

• Implement RPA for automating repetitive tasks such as data transfer and formatting.

• Consider cloud-based AI solutions that offer scalability and collaboration tools.

4. Ensure High-Quality Data Input

AI systems are only as good as the data they are trained on. Inconsistent, incomplete, or erroneous data can lead to flawed outputs and compliance risks.

Best Practices:

• Invest in data quality management—ensure source data is clean, complete, and standardized.

• Use structured data formats such as E2B(R3) where possible.

• Employ data harmonization techniques to align diverse data sources (e.g., safety databases, clinical systems, literature databases).

5. Integrate with Existing Systems

AI should not operate in silos. It must seamlessly integrate with your pharmacovigilance databases, signal detection systems, and regulatory submission platforms.

Best Practices:

• Choose AI solutions with strong interoperability and API capabilities.

• Ensure two-way data flow between AI tools and legacy systems.

• Conduct integration testing to validate data accuracy and process continuity.

6. Collaborate Across Functions

Aggregate reporting is a cross-functional activity involving pharmacovigilance, regulatory affairs, medical writing, clinical, and IT teams. AI implementation should follow the same collaborative model.

Best Practices:

• Form a cross-functional task force to guide AI implementation.

• Assign clear roles and responsibilities for AI model oversight, validation, and updates.

• Involve medical writers early to ensure AI-generated content meets clinical and scientific standards.

7. Validate AI Outputs

Regulators demand transparency in how safety decisions are made. That means AI models used in aggregate reporting must be validated and their outputs traceable.

Best Practices:

• Conduct model validation using historical reports and controlled test data.

• Use human-in-the-loop approaches—where experts review and refine AI-generated content.

• Document every step of AI logic, training data, version history, and validation outcomes for audit readiness.

8. Maintain Human Oversight

While AI enhances efficiency, it should not replace human judgment in aggregate reporting. Human oversight ensures contextually appropriate interpretations and compliance with regulatory nuance.

Best Practices:

• Use AI for supporting roles, such as data pre-processing, trend identification, and first-draft generation.

• Let medical reviewers and safety experts make final decisions on signal evaluation, risk assessment, and recommendations.

• Periodically review AI decision paths for ethical and scientific soundness.

9. Implement Robust Change Management

AI implementation requires a cultural and operational shift. Teams must be prepared to embrace new workflows, tools, and responsibilities.

Best Practices:

• Conduct training and awareness programs tailored to each function (e.g., pharmacovigilance, IT, QA).

• Use pilot programs to test AI solutions in limited environments before scaling up.

• Create feedback loops for continuous improvement based on end-user input and performance metrics.

10. Monitor and Continuously Improve

Once AI is implemented, performance monitoring and periodic updates are essential to keep it effective and compliant.

Best Practices:

• Set up KPIs such as reduction in processing time, error rate, and compliance score.

• Conduct regular audits to evaluate AI performance and identify drift or bias.

• Stay informed about AI advancements and regulatory shifts to evolve your systems proactively.

Real-World Application Example

Let’s consider a global pharmaceutical company implementing AI in PBRER preparation. They used NLP tools to extract case narratives, identify safety signals, and summarize literature references. An RPA solution automated the population of safety data tables. Medical reviewers validated AI-generated outputs and refined benefit-risk assessments.

Results:

• 40% reduction in report preparation time

• 25% fewer errors in data tables

• Enhanced compliance with regulatory timelines

• Positive feedback during inspections due to transparent AI documentation

This example underscores how applying the above best practices can transform reporting efficiency while maintaining high standards.

Common Pitfalls to Avoid

1. Lack of Validation: Unvalidated AI tools can lead to errors and compliance risks.

2. Over-reliance on Automation: Ignoring human oversight reduces the contextual quality of reports.

3. Poor Change Management: Teams not aligned with new processes may resist or misuse tools.

4. Siloed Implementation: AI initiatives not integrated across departments fail to deliver end-to-end improvements.

The Future of AI in Aggregate Reporting

The next frontier of AI in aggregate reporting lies in predictive analytics, automated literature monitoring, and real-time risk assessment. As AI becomes more sophisticated and regulators provide clearer frameworks, the pharmaceutical industry will shift from static reporting to continuous safety intelligence.

Emerging technologies like generative AI may soon assist in drafting entire report sections, summarizing patient outcomes, or translating data into multi-language reports. However, regulatory bodies will expect even greater levels of transparency, accountability, and ethical AI use.

Conclusion

AI is no longer a futuristic concept—it's a current necessity in pharmaceutical aggregate reporting. By following best practices—from regulatory alignment to robust data management, cross-functional collaboration, and continuous improvement—organizations can fully harness AI’s potential while ensuring safety, quality, and compliance.

For pharmaceutical companies aiming to stay ahead in a competitive, highly regulated landscape, implementing AI the right way in aggregate reporting is not just an efficiency booster—it’s a strategic imperative.